Rhythm Pharmaceuticals reported Q2 2026 net product revenue of $71.3 million, driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), which saw over 400 patient start forms. The company also announced positive Phase 2 results for setmelanotide in Prader-Willi syndrome and preliminary data for RM-718 in acquired HO. Rhythm maintains a strong cash position of $330.9 million and expects its cash to fund operations for at least 24 months.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved